Handa's Generic Dexilant Infringes Takeda IP, Judge Hears
Handa Pharmaceuticals should be blocked from making a generic version of the acid-reflux drug Dexilant because the drug cannot be produced without infringing Takeda Pharmaceutical Co.'s patented manufacturing process, Takeda argued...To view the full article, register now.
Already a subscriber? Click here to view full article